AOD 9604 – 5MG

What Is AOD 9604?

AOD 9604 peptide is a synthetic analog of growth hormone designed with the intention of mitigating obesity and aiding weight loss. The peptide is a modified fragment of the growth hormone where the last 16 amino acids (176-191) have been reproduced as a specific peptide, closely related to GH Fragment 176-191, called AOD 9604. It also has a tyrosine residue to replace the first amino acid at the N-terminus, which researchers consider to help increase the stability of the peptide.⁽¹⁾

More specifically, AOD 9604 is considered the lipolytic fragment of GH as different parts of the GH molecule appear to have different potentials. For instance, studies suggest that out of its 191 amino acid structure “the N-terminal region exhibits an insulin-potentiating action, while amino acids 108 - 129 of hGH were found to evoke high mitogenic responses.”⁽²⁾

 

How Is AOD 9604 Thought to Work?

AOD 9604 peptide was developed in the 1990s in an effort to develop proteins which might exhibit anti-obesity properties similar to Growth Hormone (hGH). Rigorous scientific studies and experiments have since been conducted to determine the potential action of AOD 9604 in lipolysis.⁽¹⁾ Lipolysis is a term to describe the process through which stored fats or triglycerides in fat cells are broken down into glycerol and free fatty acids, which may be used as an energy source by other cells. Enzymes such as lipase appear to play a critical role in this process, helping in the breakdown of these fats. It's possible that AOD9604 may influence the fat cells and lipolytic receptors, particularly given its observed association with changes in weight and fat in murine models. Research study findings indicate that the fragment seems to have the capacity to amplify lipolytic sensitivity following its introduction. Furthermore, the study hypothesizes a potential interaction of AOD9604 with the beta-adrenergic pathway, especially concerning the beta(3)-adrenergic receptors (beta(3)-AR), which are considered to be key lipolytic receptors found in fat cells. While it is not entirely clear, the expression level of beta(3)-AR RNA, the primary lipolytic receptor in fat cells, was observed to increase in the presence of AOD 9604. This could possibly suggest that the peptide might be playing a role in enhancing the sensitivity of these lipolytic receptors, potentially making them more responsive to lipolytic stimuli. However, it is essential to note that while the peptide appears to elevate the expression of beta(3)-AR, it may not act directly through the beta(3)-AR to induce its potential lipolytic action.

Scientists and researchers have suggested that the modified portion of the hGH in the AOD 9604 peptide may be responsible for significantly inducing the fat burning process, possibly without stimulating the production of Insulin-like Growth Factor IGF 1, as opposed to the natural growth hormone.

 

AOD 9604 Specifications

Name	AOD 9604
Other known names	Tyr-hGH Fragment 177-191, AOD9604
Sequence	Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (16 amino acids; disulfide bridge between Cys7 and Cys14)
Molecular formula	C78H123N23O23S2
Molecular weight	1815.12 g/mol
CAS number	221231-10-3
Synthesis	Solid-phase peptide synthesis, US
Form	Lyophilized powder
Amount per vial	5 mg
Purity	>99% (HPLC)
Storage	−20 °C, dry, protected from light
SKU	P-AOD9604-5

 

What Does Research Show About AOD 9604?

How May AOD 9604 Affect Lipolytic Activity in Research?

Key finding: In obese lab models, 14 days of exposure to AOD 9604 reduced body weight and body fat and increased beta⁽³⁾-adrenergic receptor RNA expression; in beta⁽³⁾-AR knock-out models, AOD 9604 still increased energy expenditure and fat oxidation in an acute experiment, suggesting that its lipolytic action is not mediated directly through this receptor.⁽¹⁾

Early studies were carried out on obese mice where the AOD 9604 peptide was periodically introduced for 14 days. Following the experiment, the results reported a reduction in weight and excess fat. These results appeared directly correlated with the increased levels of major lipolytic receptors, beta(3)-AR, found in the fat cells. AOD 9604 peptide appeared to exhibit action similar to hGH wherein both may be capable of increasing repressed levels of lipolytic receptors in obese mice as compared to the lean mice. To confirm whether the lipolytic action of AOD 9604 might merely be associated with the increased lipolytic receptor levels, additional studies were carried out where AOD 9604 was given to mice with knocked out lipolytic receptors. Further analysis suggested that the AOD 9604 peptide enacted the lipolytic action via increased energy expenditure and fat oxidation.⁽¹⁾ Both these findings on chronic and acute action of AOD 9604 suggested that while enhanced beta(3)-AR expression may have played a role in the chronic action of the compound, beta(3)-AR might not be the sole arbiter in this reaction. Oxidation and enhanced energy expenditure appeared to be vital in the proposed action of the peptide.

In 2000, a research study was carried out in obese Zucker rats where the AOD 9604 peptide was given daily for 19 consecutive days. Following the study, weight gain appeared to be reduced by over 50%, in comparison to the rats given a placebo. Further analysis suggested that the adipose tissues of the AOD 9604 peptide animals had increased lipolytic activity and no marked insulin sensitivity interruption in the animals.⁽³⁾

What Does Research Suggest About AOD 9604 and Obesity?

In 2004, clinical trials observed the actions of the peptide in 300 obese subjects who were given the peptide for 12 weeks. The rate of weight loss remained consistent throughout the study period. The trial results noted minor improvement exhibited in the subjects’ cholesterol profiles and glucose tolerance levels.⁽⁴⁾

What Does Research Show About AOD 9604 and Cell Regeneration?

Key finding: In a lab model of collagenase-induced knee osteoarthritis, AOD 9604 delivered into the joint improved cartilage morphology and histology scores compared with saline, and AOD 9604 combined with hyaluronic acid was more effective than either alone and shortened the lameness period.⁽⁵⁾

Additional research was conducted to study the regenerative potential of the peptide. In 2015, 32 lab models were divided into four groups of eight, and each group was experimented with a placebo, AOD 9604, hyaluronic acid, or a combination of AOD 9604 and hyaluronic acid once weekly for 4 weeks. After the study, these models were assessed morphologically and histopathologically to determine the degree of cartilage degeneration. It was concluded that the models which involved the combination of AOD 9604 with hyaluronic acid apparently exhibited the least degeneration. Thus, it was suggested by the researchers that AOD 9604 might exhibit potential to enhance cartilage regeneration and cartilage repair in some capacity.⁽⁵⁾

This may be due to the potential role of AOD 9604 in cellular differentiation processes and, potentially, in the synthesis of proteins important for tissue repair. According to an in vitro study, AOD 9604 may possibly enhance the differentiation of adipose mesenchymal stem cells into bone⁽⁵⁾. These stem cells, which are typically found within fat tissue, may have the potential to evolve into various cell types. It has been hypothesized that under the influence of AOD 9604, these stem cells may show a predisposition to differentiate into bone cells. Moreover, when the research was conducted on isolated bovine chondrocytes, it appeared that there might be an increased production of proteoglycan and collagen. Chondrocytes are cells believed to be found within cartilage tissue, and they possibly play a role in producing and maintaining the extracellular matrix, which consists of components like collagen and proteoglycans. It is posited that the presence of AOD 9604 could stimulate these chondrocytes to produce more of these vital components. The study also hints at the idea that AOD 9604 might promote the differentiation of myoblasts into C₂C₁₂ cells. Myoblasts are thought to be precursor muscle cells, and C₂C₁₂ cells are a type of murine model muscle cell line. From what the study suggests, AOD 9604 may assist in the transition of these precursor cells into a more mature form. The research seems to underline the potential role AOD 9604 might have in processes connected to the repair of bone, cartilage, and muscle tissues.

How May AOD 9604 Affect Cancer Cells in Laboratory Research?

Key finding: In laboratory tests, chitosan nanoparticles loaded with both the hGH fragment 176-191 and doxorubicin showed greater anti-proliferative activity against MCF-7 breast cancer cells than nanoparticles loaded with doxorubicin alone; docking simulations suggested the fragment enhanced doxorubicin binding to several breast cancer protein targets.⁽⁶⁾

The peptide may be able to bind (target) tumor-related proteins to enhance tumor drug accumulation and local cytotoxicity.⁽⁶⁾ The hGH fragment AOD 9604 may potentially play a pivotal role in cancer cell research, as it has been observed to enhance the anticancer efficacy of doxorubicin, a commonly recognized chemotherapeutic agent. One study utilized chitosan nanoparticles, a biocompatible and biodegradable polymer, as a carrier for doxorubicin and AOD 9604.⁽⁶⁾ The research team hypothesized that AOD 9604 possibly enhanced the doxorubicin binding to multiple breast cancer cell protein targets, thereby exhibiting greater anti-proliferative activity against the MCF-7 breast cancer cell line compared to chitosan loaded with doxorubicin alone. This suggests that AOD 9604 may potentially augment the anti-cancer potency of doxorubicin while possibly minimizing unintended actions associated with non-target tissue exposure. In conclusion, multiple studies have suggested that the peptide may significantly induce lipolysis and possibly prevent lipogenesis by mimicking natural hGH.

 

AOD 9604 Certificate of Analysis

Batch / lot	C74106
Test date	7/22/2026
Testing laboratory	Vanguard Laboratory
Method	HPLC-UV/VIS (identity and purity)
Purity result	99.08%
Full report	Download the AOD 9604 COA (PDF)

AOD 9604 peptide is available for research and laboratory purposes only. We offer free shipping in the US for orders over $200. Please review our Terms and Conditions before ordering.

 

AOD 9604 Frequently Asked Questions

 

References:

1. Heffernan, M., Summers, R. J., Thorburn, A., Ogru, E., Gianello, R., Jiang, W. J., & Ng, F. M. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182–5189. https://doi.org/10.1210/endo.142.12.8522
2. Moré, M. I., & Kenley, D. (2014). Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. Journal of Endocrinology and Metabolism, 4(3), 64–77. https://doi.org/10.14740/jem213w
3. Ng, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., & Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone research, 53(6), 274–278. https://doi.org/10.1159/000053183
4. News-Medical. (2004, December 16). Obesity drug codenamed AOD 9604 highly successful in trials. News-Medical.net.
5. Kwon, D. R., & Park, G. Y. (2015). Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Annals of clinical and laboratory science, 45(4), 426–432. https://pubmed.ncbi.nlm.nih.gov/26275694/
6. Habibullah, M. M., Mohan, S., Syed, N. K., Makeen, H. A., Jamal, Q. M. S., Alothaid, H., Bantun, F., Alhazmi, A., Hakamy, A., Kaabi, Y. A., Samlan, G., Lohani, M., Thangavel, N., & Al-Kasim, M. A. (2022). Human growth hormone fragment 176-191 peptide enhances the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells. Drug design, development and therapy, 16, 1963–1974. https://doi.org/10.2147/DDDT.S367586

Related reading: AOD 9604 research in lipolysis, cell regeneration and cancer and AOD9604 and fat cell breakdown in adipocytes.

Last updated Oct 16, 2026 · Scientific review: Dr. Dimitar Marinov, MD, PhD